INTRODUCTION: Developments in DNA-diagnostic techniques allow us to identify a significant proportion of patients with gene mutations causing familial heart diseass (arrhythmia syndromes, cardiomyopathies etc.) and to identify family members in early stages of the disease and/or even before symptoms occur. Early treatment can prevent sudden cardiac death and disease progression. However, data on long-term outcome in unselected genotyped patients are scarce due to a lack of large registries. In 2005, a national internet-based registry for familial heart diseases in the Netherlands, named GENCOR, was developed in collaboration with the Interuniversity Cardiology Institute of the Netherlands (ICIN). OBJECTIVES: GENCOR aims to assess the prevalence of familial heart diseases in patients and families in the Netherlands and to facilitate research to improve the quality of diagnostics and therapy in familial heart diseases. METHODS: Patients who visit the (cardio)genetic outpatient clinic are informed about GENCOR and asked to consent to the storage of information about cardiac examinations, family history and DNA diagnostics from all their visits. Patient data are entered into the internet-based GENCOR database by the cardiologist or clinical geneticist in attendance. Additional information can be stored for scientific research. RESULTS: Four university hospitals are actively obtaining informed consent from the patients, which resulted in the inclusion of more than 300 patients. In 2006, more university hospitals will start using GENCOR and the aim is that all university hospitals will participate. Three research projects have already started using GENCOR. CONCLUSION: GENCOR is already a success, regarding the number of included patients and the related research projects set up within a limited period of time. GENCOR provides easy internet-based access for authorised cardiologists, clinical geneticists and scientists throughout the country.
INTRODUCTION: Developments in DNA-diagnostic techniques allow us to identify a significant proportion of patients with gene mutations causing familial heart diseass (arrhythmia syndromes, cardiomyopathies etc.) and to identify family members in early stages of the disease and/or even before symptoms occur. Early treatment can prevent sudden cardiac death and disease progression. However, data on long-term outcome in unselected genotyped patients are scarce due to a lack of large registries. In 2005, a national internet-based registry for familial heart diseases in the Netherlands, named GENCOR, was developed in collaboration with the Interuniversity Cardiology Institute of the Netherlands (ICIN). OBJECTIVES: GENCOR aims to assess the prevalence of familial heart diseases in patients and families in the Netherlands and to facilitate research to improve the quality of diagnostics and therapy in familial heart diseases. METHODS:Patients who visit the (cardio)genetic outpatient clinic are informed about GENCOR and asked to consent to the storage of information about cardiac examinations, family history and DNA diagnostics from all their visits. Patient data are entered into the internet-based GENCOR database by the cardiologist or clinical geneticist in attendance. Additional information can be stored for scientific research. RESULTS: Four university hospitals are actively obtaining informed consent from the patients, which resulted in the inclusion of more than 300 patients. In 2006, more university hospitals will start using GENCOR and the aim is that all university hospitals will participate. Three research projects have already started using GENCOR. CONCLUSION: GENCOR is already a success, regarding the number of included patients and the related research projects set up within a limited period of time. GENCOR provides easy internet-based access for authorised cardiologists, clinical geneticists and scientists throughout the country.
Authors: C Bezzina; M W Veldkamp; M P van Den Berg; A V Postma; M B Rook; J W Viersma; I M van Langen; G Tan-Sindhunata; M T Bink-Boelkens; A H van Der Hout; M M Mannens; A A Wilde Journal: Circ Res Date: 1999 Dec 3-17 Impact factor: 17.367
Authors: H L Tan; M T Bink-Boelkens; C R Bezzina; P C Viswanathan; G C Beaufort-Krol; P J van Tintelen; M P van den Berg; A A Wilde; J R Balser Journal: Nature Date: 2001-02-22 Impact factor: 49.962
Authors: J Peter van Tintelen; Mark M Entius; Zahurul A Bhuiyan; Roselie Jongbloed; Ans C P Wiesfeld; Arthur A M Wilde; Jasper van der Smagt; Ludolf G Boven; Marcel M A M Mannens; Irene M van Langen; Robert M W Hofstra; Luuk C Otterspoor; Pieter A F M Doevendans; Luz-Maria Rodriguez; Isabelle C van Gelder; Richard N W Hauer Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet Journal: Circulation Date: 1996-03-01 Impact factor: 29.690
Authors: E T van der Velde; Velde E T Vander; J W J Vriend; M M A M Mannens; C S P M Uiterwaal; R Brand; Barbara J M Mulder Journal: Eur J Epidemiol Date: 2005 Impact factor: 8.082
Authors: Jop H van Berlo; Willem G de Voogt; Anneke J van der Kooi; J Peter van Tintelen; Gisèle Bonne; Rabah Ben Yaou; Denis Duboc; Tom Rossenbacker; Hein Heidbüchel; Marianne de Visser; Harry J G M Crijns; Yigal M Pinto Journal: J Mol Med (Berl) Date: 2004-11-13 Impact factor: 4.599
Authors: Marielle Alders; Roselie Jongbloed; Wout Deelen; Arthur van den Wijngaard; Pieter Doevendans; Folkert Ten Cate; Vera Regitz-Zagrosek; Hans Peter Vosberg; Irene van Langen; Arthur Wilde; Dennis Dooijes; Marcel Mannens Journal: Eur Heart J Date: 2003-10 Impact factor: 29.983